About artrix

This author has not yet filled in any details.
So far artrix has created 91 blog entries.

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia2024-06-13T23:44:13-07:00

Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic

Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic2024-05-17T01:10:35-07:00

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs2024-05-09T16:40:05-07:00

Soleno Therapeutics Received Breakthrough Therapy Designation from U.S.FDA For DCCR (Diazoxide Choline) Extended-Release Tables in Prader-Willi (PWS)

Soleno Therapeutics Received Breakthrough Therapy Designation from U.S.FDA For DCCR (Diazoxide Choline) Extended-Release Tables in Prader-Willi (PWS)2024-05-09T21:06:55-07:00

Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China

Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China2024-04-28T21:45:45-07:00

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion in Cash, Leveraging Povetacicept for IgA Nephropathy and Autoimmune Diseases

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion in Cash, Leveraging Povetacicept for IgA Nephropathy and Autoimmune Diseases2024-04-13T23:53:23-07:00

Evaheart Launches EVA-Pulsar™, Second Generation Destination Therapy Left Ventricular Assist Device (LVAD) Treating Heart Failure Patients

Evaheart Launches EVA-Pulsar™, Second Generation Destination Therapy Left Ventricular Assist Device (LVAD) Treating Heart Failure Patients2024-03-08T01:11:03-08:00
Go to Top